Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., has appointed Eran Kuratz as head of supply chain and business process administration. This strategic move comes as the company positions its contract development and manufacturing organization (CDMO) for significant growth following its recent acquisition of Recipharm Israel.
Kuratz brings more than 30 years of leadership, supply chain, and operational experience across the pharmaceutical, biotechnology, medical-device, and industrial sectors. In his new role, he will oversee critical functions including procurement, contracting, inventory management, logistics, budgeting, IT and business systems, cybersecurity, and cross-functional business processes. His appointment is expected to streamline operations and enhance efficiency across the expanded CDMO platform.
The timing of this appointment is significant. In the first quarter of 2026, Scinai completed the acquisition of Recipharm Israel, adding a second development and manufacturing site in Yavne. Combined with Scinai's existing operations in Jerusalem, the expanded platform now offers a comprehensive range of services. These include biologics process development, aseptic manufacturing, sterile fill-and-finish, small-molecule active pharmaceutical ingredient development and synthesis, analytical-method development, and GMP manufacturing. This expanded capability positions Scinai as a more competitive player in the CDMO market, able to serve a broader range of clients with diverse needs.
“The addition of Eran Kuratz is a key step in optimizing our CDMO operations and ensuring we deliver high-quality services to our clients,” said a company spokesperson. “His extensive experience in supply chain management and business processes will be instrumental as we integrate and expand our manufacturing capabilities.”
The CDMO sector has seen increasing demand as pharmaceutical and biotech companies outsource manufacturing to focus on core R&D. By strengthening its operational leadership, Scinai aims to capitalize on this trend and offer a more integrated and efficient service. The company's expanded facilities in both Jerusalem and Yavne provide geographic diversity and flexibility, which is crucial for clients seeking reliable manufacturing partners.
This appointment also reflects a broader strategic focus on operational excellence. With Kuratz overseeing IT, cybersecurity, and business systems, Scinai is addressing the need for robust digital infrastructure and data security in the highly regulated biopharmaceutical industry. This holistic approach to business process administration is designed to ensure compliance and efficiency at every level.
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. Its pipeline includes candidates licensed from the Max Planck Society and PinCell S.r.l. The CDMO subsidiary, Scinai Biopharma Services, provides development and manufacturing services through its facilities in Israel. This dual focus on proprietary drug development and contract services allows the company to leverage its expertise and infrastructure for multiple revenue streams.
As the CDMO expands, the appointment of seasoned executives like Kuratz is critical to maintaining high standards and meeting client expectations. The company's investment in leadership and infrastructure signals confidence in the growing demand for specialized biopharmaceutical manufacturing. By enhancing its supply chain and business processes, Scinai is better positioned to deliver on its promises and build long-term relationships with clients.
For more information on Scinai's news and updates, visit the company's newsroom at https://ibn.fm/SCNI.
